SALT LAKE CITY, March 20, 2007 (PRIME NEWSWIRE) -- LipidViro Tech, Inc. (Company) (OTCBB:LPVT), a development-stage medical device company, announced that co-founder and Head of Research, Joseph Latino made a dinner presentation to the Long Island Investment Banking Group (LIIBG) at 5:50 p.m. on Monday, March 19, 2007, in Garden City, N.Y.
LipidViro Tech is engaged in research and commercial development of its proprietary d-OSAB technology, a multiple-therapeutic platform. The Company has initially targeted ischemic brain stroke and chronic heart failure, two diseases with few viable treatment options and markets exceeding $20 billion annually in the U.S. and EU. LipidViro's development and commercialization strategy is to move its controlled-dosage d-OSAB platform for the treatment of stroke through the European Union (EU) regulatory process. During 2007, the Company is scheduled to commence a 100-patient Phase IIa study treating patients who have suffered an ischemic brain stroke. d-OSAB targets the untreated stroke population estimated in the EU to exceed 99% of individuals afflicted. Multi-site EU Phase III studies and concurrent pre-application meetings with the FDA will follow positive clinical results from this Phase IIa trial.
"LipidViro Tech offers new technology for treating stroke and chronic heart failure, which are serious health risks, so we are particularly pleased to host this presentation by Mr. Latino," said William Jordan, LIIBG president.
About LIIBG
The LIIBG was founded in 1996 by brokers to focus on investment opportunities in small-cap and micro-cap publicly traded companies that are low-priced and undervalued, and offer attractive potential for success in their businesses and industries and growth and profitability.
About LipidViro Tech, Inc.
LipidViro Tech, Inc. is an early-stage biotechnology company engaged in research and commercial development of d-OSAB, a multi-therapeutic device-based platform. The Company's first commercial therapeutics target Ischemic Brain Stroke and Chronic Heart Failure.
Stroke is the second leading cause of death worldwide, responsible for 4.4 million deaths each year. Annually, stroke strikes more than 1.7 million people in the U.S. and EU. Seven percent of ischemic stroke patients die within 30 days, 25% die within one year. More than 50% of surviving patients have permanent disabilities that require nursing home or other long-term care. The single approved therapeutic for ischemic brain stroke patients is Tissue Plasminogen Activator (tPA). Patients are only eligible for tPA during a three-hour window from time of stroke; tPA use after three hours causes bleeding in the brain which may prove fatal. Consequently, approximately 6% of U.S. stroke patients and less than 1% of EU stroke patients utilize tPA.